Hydrochloric Acid

Hydrochloric Acid

SCHEMBL7130904

Cl.NC1Cc2ccccc2C1=O

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 3/20 0.57
CYP19A1 known ✓ P11511 1/20 0.44
ANPEP P15144 4/20 0.55
METAP1 P53582 4/20 0.50
AADAT Q8N5Z0 2/20 0.44
GOT1 P17174 1/20 0.44
KYAT1 Q16773 1/20 0.44
KYAT3 Q6YP21 1/20 0.44
TSHR P16473 1/20 0.43
S100A4 P26447 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27846771 1.00 ACHE (0.57) ACHEANPEPMETAP1AADATGOT1
Hydrochloric Acid SCHEMBL27827926 1.00 ACHE (0.57) ACHEANPEPMETAP1AADATGOT1
SCHEMBL30539131 0.98 ACHE (0.59) ACHEANPEPMETAP1AADATGOT1
SCHEMBL3063845 0.98 ACHE (0.59) ACHEANPEPMETAP1AADATGOT1
Hydrochloric Acid SCHEMBL697026 0.80 ANPEP (0.58) ANPEPCYP19A1
Hydrochloric Acid SCHEMBL10615496 0.80 ALDH1A1 (0.49) ACHEANPEP
SCHEMBL2384933 0.78 ANPEP (0.56) ACHEANPEPCYP19A1TSHR
SCHEMBL30539234 0.78 ANPEP (0.56) ACHEANPEPCYP19A1TSHR
SCHEMBL11865381 0.78 ANPEP (0.56) ACHEANPEPCYP19A1TSHR
SCHEMBL10614233 0.77 ALDH1A1 (0.50) ACHEANPEPAADATGOT1KYAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101906051-B Synthesizing method of chiral amino indanone UNIV CHENGDU TECHNOLOGY 2013-01-23 CN disclosed
CN-101906051-A Synthesizing method of chiral amino indanone UNIV CHENGDU TECHNOLOGY 2010-12-08 CN disclosed
US-20030148877-A1 Metallocenes and catalysts for olefin-polymerisation BASELL TECHNOLOGY COMPANY BV (NL) 2003-08-07 US disclosed
EP-0952978-B1 METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION BASELL POLYOLEFINE GMBH (DE) 2003-01-22 EP disclosed
US-6451724-B1 BIS(N-METHYL-5,10-DIHYDROINDENO(1,2-B)INDOL-10 -YL)TITANIUM DICHLORIDE BASELL TECHNOLOGY COMPANY BV (NL) 2002-09-17 US disclosed
EP-0952978-A1 METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION Montell Technology Company bv (NL) 1999-11-03 EP disclosed
US-5922716-A 5H-indeno 1,2-b!pyrazine-2,3-dione derivatives, their preparation and medicinal products containing them RHONE-POULENC RORER S.A. (FR) 1999-07-13 US disclosed
WO-1999024446-A1 METALLOCENES AND CATALYSTS FOR OLEFIN-POLYMERISATION MONTELL TECHNOLOGY COMPANY B.V. (NL) 1999-05-20 WO disclosed
US-4548943-A INHIBITS PROSTAGLADIN SYNTHETASE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030148877-A1 Metallocenes and catalysts for olefin-polymerisation MT-CO1, CPNE4, MT-CO3 ACHE 4601/4885CYP19A1 2313/4885ANPEP 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.